Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BX-U001 in severe COVID-19 pneumonia with ARDS
NCT04452097Phase 2Withdrawn
- Sponsor
- Baylx
- Start
- Jun 2026
- Primary completion
- Jul 2027
- Modality
- Mesenchymal Stem Cells
01
Overview
A Phase 2 trial of BX-U001 in COVID-19 pneumonia, acute respiratory distress syndrome (ARDS), sponsored by Baylx. Planned start Jun 2026; status: withdrawn.
02
Drugs
BX-U001
03
Conditions
COVID-19 pneumoniaacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04452097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04452097.